Long-term complete response in a patient with postoperative recurrent ALK-rearranged lung adenocarcinoma treated with crizotinib: A case report.
Abstract Anaplastic lymphoma kinase (ALK) gene rearrangements are identified in approximately 5% of patients with non-small cell lung cancer (NSCLC). Despite initial dramatic responses to ALK inhibitors, the majority of patients relapse within 1 year, owing to the development of resistance. Herein we present a case of variant type 2 ALK-rearranged lung adenocarcinoma recurrence with multiple lung metastasis that maintained complete response over 5 years with crizotinib, which is the first approved ALK inhibitor. The efficacy of crizotinib may vary among ALK fusion variants and thus, variant type may represent an i...
Source: Clinical Lung Cancer - August 11, 2019 Category: Cancer & Oncology Authors: Kosaka T, Yajima T, Yamaki E, Nakazawa S, Tomizawa K, Onozato R, Yamazaki A, Hirato J, Yatabe Y, Shimizu K, Mogi A, Shirabe K Tags: Mol Clin Oncol Source Type: research

Efficacy of smoking cessation with varenicline plus counselling for e-cigarettes users (VAREVAPE): A protocol for a randomized controlled trial.
Abstract Tobacco smoking is a global pandemic that poses substantial health burdens and costs. With nearly six million deaths annually, smoking is the single most important cause of avoidable premature mortality in the world, mainly from lung cancer, coronary heart disease, chronic obstructive pulmonary disease and stroke. Smoking is a very difficult addiction to break, even for those with a strong desire to quit. Electronic cigarettes are an attractive long-term alternative source of nicotine to conventional cigarettes because of their many similarities with smoking. Electronic cigarette users report buying them ...
Source: Clinical Lung Cancer - August 9, 2019 Category: Cancer & Oncology Authors: Caponnetto P, Maglia M, Polosa R Tags: Contemp Clin Trials Commun Source Type: research

Cancer Screening in Women.
Abstract Advancements in cancer screening techniques have allowed for earlier detection of cancer at premalignant or early stages of disease. Several organizations have guidelines for screening strategies for breast, cervical, colon, and lung cancer. Ovarian cancer remains the deadliest cancer of the female reproductive tract; however, guidelines have yet to be shown effective in identifying ovarian cancer at earlier stages. It is important that providers familiarize themselves with up-to-date screening strategies in women at average risk and at increased risk of disease. The provider's role in guiding patients to...
Source: Clinical Lung Cancer - August 7, 2019 Category: Cancer & Oncology Authors: Vogell A, Evans ML Tags: Obstet Gynecol Clin North Am Source Type: research

Association between EGFR exon 19 or exon 21 mutations and survival rates after first-line EGFR-TKI treatment in patients with non-small cell lung cancer.
Abstract Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) who have an EGFR mutation. However, little has been reported about the association between EGFR exon 19 deletions or an exon 21 mutation (specifically the L858R point mutation) and survival rates following first-line EGFR-TKI treatment in patients with NSCLC. As a retrospective study, 72 patients with stage IIIB/IV NSCLC carrying EGFR mutations (exon 19 deletions or an exon 21 mutation) were enrolled between 1 January 2008 and 31 December 2013, and...
Source: Clinical Lung Cancer - August 7, 2019 Category: Cancer & Oncology Authors: Jiang H, Zhu M, Li Y, Li Q Tags: Mol Clin Oncol Source Type: research

Surgical Treatment of Lung Cancer.
Abstract Lung cancer is the leading cause of cancer-related death and the second most diagnosed cancer in the United States. Surgical intervention is most applicable to early-stage lung cancer diagnoses and considered the best curative option. Multiple surgical techniques are now available, including wedge resection, segmentectomy, lobectomy, and pneumonectomy. Robotics and video-assistance are commonly used in wedge resection and sometimes used for segmentectomy. Regardless of the technique, focused clinical management of the patient following lung cancer surgery by nurses and nurse practitioners remains a priori...
Source: Clinical Lung Cancer - July 30, 2019 Category: Cancer & Oncology Authors: Hoy H, Lynch T, Beck M Tags: Crit Care Nurs Clin North Am Source Type: research

EGFR mutant locally advanced non-small cell lung cancer is at increased risk of brain metastasis.
Conclusion: Patients with EGFR+ LA-NSCLC have a significantly higher likelihood of developing brain metastasis after standard combined modality therapy, independent of their longer overall survival. This high-risk genotypic subgroup may benefit from routine surveillance with brain MRI to allow early salvage with targeted systemic- and/or radiation-therapies. PMID: 31341973 [PubMed] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - July 27, 2019 Category: Cancer & Oncology Authors: Mitra D, Chen YH, Li R, Hermann G, Atkins K, Kozono D, Baldini EH, Aizer A, Chukwueke U, Mak RH Tags: Clin Transl Radiat Oncol Source Type: research

Resection of anterior mediastinal ectopic pancreas by right thoracoscopy: A case report.
Abstract Ectopic pancreas is uncommon in the anterior mediastinum. Herein, a 32-year-old woman presented to our institution for investigation of an abnormal mediastinal shadow on chest computed tomography. The patient underwent complete surgical resection of the anterior mediastinal mass by right thoracoscopy, and the postoperative pathology examination confirmed the diagnosis of ectopic pancreas. There were no clinical signs of pancreatitis. No recurrence or metastasis was observed during a follow-up period of 3 years. English language medical literature was also searched in order to identify other case reports d...
Source: Clinical Lung Cancer - July 20, 2019 Category: Cancer & Oncology Authors: Zhao H, Zhang Z, Li X, Liu J, Zhang H, Chen G, Chen J Tags: Mol Clin Oncol Source Type: research

Pseudoprogression presenting as intestinal perforation in non-small cell lung cancer treated with anti-PD-1: A case report.
We report on a case of pseudoprogression, which was presented as intestinal perforation after pembrolizumab immunotherapy for NSCLC. A-54-year-old man with stage IV NSCLC received pembrolizumab therapy. The patient was admitted to our hospital because of acute abdominal pain and the computed tomography scan revealed diffuse wall thickening of the small bowel with free intraperitoneal air. Intestinal perforation was suspected and surgical resection was performed. Histological evaluation of the resected specimen showed infiltrated lymphocytes positive for CD3, CD8 with necrotic tumor cells, suggestive of an immune reaction. ...
Source: Clinical Lung Cancer - July 11, 2019 Category: Cancer & Oncology Authors: Kim HK, Baek SW, Jeong Y, Yang Y, Kwon J, Han HS, An JY, Woo CG, Lee OJ, Lee TG, Lee KH Tags: Mol Clin Oncol Source Type: research

Thyroid Cancer Bone Metastasis: Survival and Genomic Characteristics of a Large Tertiary Care Cohort.
CONCLUSION: Patients with DTC can benefit from early treatment with external beam radiation therapy, especially those who develop bone metastasis within 3 years of primary TC diagnosis. Kinase inhibitor treatment tended to prolong survival but not in a statistically significant manner. Sex, age, and TERT or BRAF genetic mutations did not significantly affect the prognosis. PMID: 31274625 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - July 7, 2019 Category: Cancer & Oncology Authors: Kondraciuk JD, Rice SL, Zhou X, Gharzeddine K, Knezevic A, Spratt DE, Sabra M, Larson SM, Grewal RK, Osborne JR Tags: Clin Nucl Med Source Type: research

Identification and diagnostic value of pleural fluid periostin and serum periostin of malignant pleural effusions in patients with non-small-cell lung cancer.
CONCLUSION: Combined detection of sPOSTN/pADA, pCA199/pADA, and pCA199/pPOSTN can be used as a good indicator for MPE caused by NSCLC. PMID: 31268191 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - July 3, 2019 Category: Cancer & Oncology Authors: Wang J, Fu J, Shen Q, Zhang F, Wang Y, Wu LL Tags: J Clin Lab Anal Source Type: research

A review of whole brain radiotherapy outcomes in a high epidermal growth factor receptor mutation rate population: Does QUARTZ apply in Asia?
We report the patient characteristics and survival outcomes of our local population in comparison with theirs. METHODS: Medical records of patients who received WBRT in two tertiary hospitals over 18 months were reviewed. Characteristics and survival outcomes of patient with NSCLC receiving WBRT for the first time were evaluated. Patients with prior excision of BM or stereotactic radiotherapy were excluded. Treatment details including radiotherapy dose and use of tyrosine kinase inhibitors (TKIs) were recorded. RESULTS: Between January 2015 and June 2016, 116 patients with NSCLC received WBRT for their BM. Their ...
Source: Clinical Lung Cancer - July 2, 2019 Category: Cancer & Oncology Authors: Ng IW, Tey JCS, Chia DWT, Yee CM, Cheo TST Tags: Asia Pac J Clin Oncol Source Type: research

Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens.
CONCLUSIONS: Trunk driver mutations are highly concordant in primary and metastatic tumors. Discordance of trunk drivers, once confirmed, may suggest a second primary cancer. Guidelines are recommended to establish standard operating procedures for validation of discordant trunk drivers. PMID: 31264684 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - July 2, 2019 Category: Cancer & Oncology Authors: Tseng LH, De Marchi F, Pallavajjalla A, Rodriguez E, Xian R, Belchis D, Gocke CD, Eshleman JR, Illei P, Lin MT Tags: Am J Clin Pathol Source Type: research

Targeting ceramide synthase 6-dependent metastasis-prone phenotype in lung cancer cells.
a R, Tamiya-Koizumi K, Murate T, Nakamura M, Kyogashima M, Takahashi T PMID: 31264973 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - July 2, 2019 Category: Cancer & Oncology Authors: Suzuki M, Cao K, Kato S, Komizu Y, Mizutani N, Tanaka K, Arima C, Tai MC, Yanagisawa K, Togawa N, Shiraishi T, Usami N, Taniguchi T, Fukui T, Yokoi K, Wakahara K, Hasegawa Y, Mizutani Y, Igarashi Y, Inokuchi JI, Iwaki S, Fujii S, Satou A, Matsumoto Y, Ueo Tags: J Clin Invest Source Type: research

The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
CONCLUSIONS: The dual PI3K/mTOR inhibition by BEZ235 is an effective antitumor strategy for enhancing the efficacy of chemotherapy or targeted therapy, even as a monotherapy, to restrict tumor growth in lung cancer treatment. PMID: 31262325 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Wu YY, Wu HC, Wu JE, Huang KY, Yang SC, Chen SX, Tsao CJ, Hsu KF, Chen YL, Hong TM Tags: J Exp Clin Cancer Res Source Type: research

Identification of S100A14 as a metastasis-promoting molecule in a murine organotropic metastasis model.
Abstract Cancer metastasis shows great diversity in target organs, routes and molecular mechanisms depending on the type of cancer and even on the individual patients. To identify key molecules involved in metastasis, we constructed a murine model system including multiple sublines with different organotropism and pathways of metastasis. We selected metastatic sublines from a murine mammary tumor cell line MCH66. Using this model, we extracted metastasis-related molecules by gene expression screening methods and verified their metastasis-promoting effects by gene knockdown or overexpression experiments. For the ca...
Source: Clinical Lung Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Sugino T, Ichikawa-Tomikawa N, Tanaka M, Shishito N, Miura T, Abe M, Muramatsu K, Oishi T, Kakuda Y, Kawata T, Akiyama Y Tags: Clin Exp Metastasis Source Type: research

Pro-gastrin-releasing peptide as a marker for the Ewing sarcoma family of tumors.
CONCLUSIONS: Serum ProGRP levels were elevated in half of the patients with ESFTs and reflected therapeutic response. ProGRP is a reliable tumor marker for the diagnosis of ESFTs and evaluation of treatment response. PMID: 31264078 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Honda Y, Katagiri H, Takahashi M, Murata H, Wasa J, Hosaka S, Ishida Y, Ito I, Muramatsu K, Mochizuki T, Matsuyama Y, Yamaguchi K Tags: Int J Clin Oncol Source Type: research

Serum lipidome screening in patients with stage I non-small cell lung cancer.
Abstract The ability of early lung cancer diagnosis is an unmet need in clinical practice. Lung cancer metabolomic analyses conducted so far have demonstrated several abnormalities in cancer lipid profile providing a rationale for further study of blood lipidome of the patients. In the present research, we performed a targeted lipidome screening to select molecules that show promise for early lung cancer detection. The study was conducted on serum samples collected from newly diagnosed, stage I non-small cell lung cancer (NSCLC) patients and non-cancer controls. A high-throughput mass spectrometry-based platform w...
Source: Clinical Lung Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Klupczynska A, Plewa S, Kasprzyk M, Dyszkiewicz W, Kokot ZJ, Matysiak J Tags: Clin Exp Med Source Type: research

Growth patterns of small peripheral squamous cell carcinoma of the lung and their impacts on pathological and biological characteristics of tumor cells.
CONCLUSIONS: In this study, we clearly showed that cancer cells presenting with ASF represents a "less invasive phenotype" in peripheral SCC. PMID: 31115670 [PubMed - indexed for MEDLINE] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Omori T, Aokage K, Nakamura H, Katsumata S, Miyoshi T, Sugano M, Kojima M, Fujii S, Kuwata T, Ochiai A, Ikeda N, Tsuboi M, Ishii G Tags: J Cancer Res Clin Oncol Source Type: research

Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer.
Abstract PURPOSE: Based on an exceptionally durable response to pemetrexed observed in some patients with metastatic NSCLC, the predictive value of pemetrexed sensitivity to outcomes of subsequent systemic treatment was investigated. METHODS: We retrospectively reviewed the patients with metastatic non-squamous NSCLC treated with pemetrexed monotherapy as their first- or second-line chemotherapy between November 2006 and February 2015. Good (top 5% longest) and poor responders (bottom 12% shortest) were defined according to the duration of pemetrexed maintenance. The first and second post-pemetrexed (PP) syst...
Source: Clinical Lung Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Park JH, Kwon BS, Park SJ, Ji W, Yoon S, Choi CM, Lee JC Tags: J Cancer Res Clin Oncol Source Type: research

Safety and efficacy of 125I brachytherapy for bilateral lung recurrences from hepatocellular carcinoma after resection or ablation.
Abstract PURPOSE: To evaluate the safety and efficacy of 125I brachytherapy to treat bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation. MATERIALS AND METHODS: We retrospectively recruited 95 patients with bilateral lung recurrences from hepatocellular carcinoma (HCC) after resection or ablation who had received 3-6-month sorafenib with or without stereotactic body radiotherapy (SBRT), from October 2011 to January 2015; patients were then randomly divided into two groups, 44 patients received computed tomography (CT)-guided 125I brachytherapy (group A), and 51 patients ...
Source: Clinical Lung Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Xiang Z, Bai M, Li G, Zou B, Zhong Z, Gao F, Wu C, Huang M, Zhang F Tags: J Cancer Res Clin Oncol Source Type: research

Elevated integrin α6 expression is involved in the occurrence and development of lung adenocarcinoma, and predicts a poor prognosis: a study based on immunohistochemical analysis and bioinformatics.
Elevated integrin α6 expression is involved in the occurrence and development of lung adenocarcinoma, and predicts a poor prognosis: a study based on immunohistochemical analysis and bioinformatics. J Cancer Res Clin Oncol. 2019 Jul;145(7):1681-1693 Authors: Shen J, Xu J, Chen B, Ma D, Chen Z, Li JC, Zhu C Abstract OBJECTIVE: To study integrin α6 expression in lung adenocarcinoma tissue through comparison with matching adjacent non-cancerous tissues as well as elucidating the correlation between integrin α6 expression with the clinical parameters of lung adenocarcinoma. We also explo...
Source: Clinical Lung Cancer - July 1, 2019 Category: Cancer & Oncology Authors: Shen J, Xu J, Chen B, Ma D, Chen Z, Li JC, Zhu C Tags: J Cancer Res Clin Oncol Source Type: research

Clinical Outcomes Following Stereotactic Body Radiation Therapy (SBRT) for Stage I Medically Inoperable Small Cell Lung Carcinoma: A Multi-Institutional Analysis From the RSSearch Patient Registry.
CONCLUSIONS: SBRT was well-tolerated in the treatment of stage I SCLC with excellent LC achieved. Patients with T1N0 stage IA SCLC were noted to have improved PFS and OS following SBRT as compared with T2N0 Stage IB SCLC. Adjuvant chemotherapy was found to result in improved OS for stage I SCLC patients over SBRT alone. PMID: 31232723 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - June 25, 2019 Category: Cancer & Oncology Authors: Singh R, Ansinelli H, Sharma D, Jenkins J, Davis J, Vargo JA, Sharma S Tags: Am J Clin Oncol Source Type: research

Association of Rurality With Survival and Guidelines-Concordant Management in Early-stage Non-Small Cell Lung Cancer.
Abstract BACKGROUND: Rural populations of the United States have not experienced a similar degree of decline in lung cancer mortality recently seen nationwide. Several investigations examining survival differences in rural lung cancer patients have been incongruent. We investigated the association of rural residence with survival outcomes and receipt of guidelines-concordant treatment in early-stage non-small cell lung cancer (NSCLC). METHODS: Retrospective study of National Cancer Data Base patients with NSCLC diagnosed from 2004 to 2015. Comparisons of survival outcomes and guidelines-concordant management ...
Source: Clinical Lung Cancer - June 25, 2019 Category: Cancer & Oncology Authors: Nicoli CD, Sprague BL, Anker CJ, Lester-Coll NH Tags: Am J Clin Oncol Source Type: research

The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies.
Abstract Immunotherapy has led to unprecedented improvement in the treatment and prognosis of high-risk resectable and metastatic disease across cancer types. Nowhere is this better highlighted than in the management of advanced and metastatic melanoma with the introduction of molecularly targeted therapies and immune checkpoint inhibitors. Following their success in melanoma, immunotherapies have also been evaluated and their use approved in the management across a variety of other solid malignancies in the neoadjuvant, adjuvant, and advanced/metastatic setting. This review provides an overview of the current lan...
Source: Clinical Lung Cancer - May 15, 2019 Category: Cancer & Oncology Authors: Keung EZ, Wargo JA Tags: Surg Oncol Clin N Am Source Type: research

Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy.
Abstract Purpose: To analyze associations between heart and lung dose and overall survival (OS) in patients with esophageal cancer who received concurrent chemo-radiotherapy (CCRT) with or without surgery. Patients and methods: Patients received intensity-modulated radiation therapy (median dose 50.4 Gy) from 2004 through 2016. Cutoff points for continuous variables were calculated using the method of Contal and O'Quigley. Kaplan-Meier method with log-rank tests was used to calculate survival. OS was analyzed with both univariate and multivariable Cox models. Results: In all, 560 patients were analyzed...
Source: Clinical Lung Cancer - May 15, 2019 Category: Cancer & Oncology Authors: Xu C, Guo L, Liao Z, Wang Y, Liu X, Zhao S, Wang J, Yuan Z, Wang P, Lin SH Tags: Clin Transl Radiat Oncol Source Type: research

Prognostic impact of serum transthyretin in patients with non-small cell lung cancer.
Abstract The identification of novel biomarkers is of great importance for improving the outcome of patients with non-small cell lung cancer (NSCLC). Therefore, the aim of the present study was to determine whether the serum transthyretin (TTR) level could be used as a novel prognostic biomarker for patients with NSCLC. Serum TTR levels, and nutritional and inflammatory parameters were examined prior to treatment in 42 patients with NSCLC. Candidates for independent predictors of prognostic factors were subjected to univariate and multivariate analyses using a Cox proportional hazard model. IL-12-productivity, ser...
Source: Clinical Lung Cancer - May 1, 2019 Category: Cancer & Oncology Authors: Shimura T, Shibata M, Inoue T, Owada-Ozaki Y, Yamaura T, Muto S, Hasegawa T, Shio Y, Suzuki H Tags: Mol Clin Oncol Source Type: research

The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations.
Abstract The present retrospective study was conducted to evaluate the efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC) harboring driver mutations. Patients with NSCLC harboring driver mutations who received ICIs (nivolumab or pembrolizumab) were reviewed in Hirosaki University and Aomori Prefectural Central Hospital. There were 139 patients who received molecular targeted drugs, including 24 patients treated with ICIs. Patient characteristics were as follows: Male/female, 5/19; median age 68 (range 39-82); smoking/non-smoking, 6/18; PS 0-1/2, 20/4; drive...
Source: Clinical Lung Cancer - May 1, 2019 Category: Cancer & Oncology Authors: Sakamoto H, Tanaka H, Shiratori T, Baba K, Ishioka Y, Itoga M, Taima K, Hasegawa Y, Takanashi S, Tasaka S Tags: Mol Clin Oncol Source Type: research

Meningeal carcinomatosis from bladder cancer: A case report and review of the literature.
Abstract A 66-year-old Japanese male patient was referred to Saitama Medical University International Medical Center for treatment of bladder cancer (clinical stage T2 or higher without metastasis), and underwent radical cystectomy with pelvic lymphadenectomy. The histopathological diagnosis was high-grade urothelial carcinoma (pathological stage T2bN2, ly1, v0) and 2 cycles of adjuvant systemic chemotherapy (gemcitabine plus cisplatin) were administered. At 15 months after the operation, mediastinal and lung hilar lymph nodes and multiple bone metastases were identified on computed tomography imaging. After 3 cyc...
Source: Clinical Lung Cancer - April 24, 2019 Category: Cancer & Oncology Authors: Umezawa Y, Shirotake S, Kaneko G, Nishimoto K, Okada Y, Uchino A, Yasuda M, Oyama M Tags: Mol Clin Oncol Source Type: research

Paclitaxel for relapsed small-cell lung cancer patients with idiopathic interstitial pneumonias.
Abstract Although first-line chemotherapy is highly sensitive against small-cell lung cancer (SCLC), most patients subsequently experience disease progression. Topotecan is the standard therapy for sensitive-relapsed SCLC patients, and subgroup analysis of a randomized phase III trial suggests that amrubicin is effective for refractory-relapsed SCLC. However, because of the lack of the evidence based on clinical trials, the effectiveness of systemic chemotherapy for relapsed SCLC patients with idiopathic interstitial pneumonias (IIPs) is unclear. In the presentstudy, 17 relapsed SCLC patients with IIPs who receive...
Source: Clinical Lung Cancer - April 12, 2019 Category: Cancer & Oncology Authors: Saijo A, Hanibuchi M, Ogino H, Otsuka K, Goto H, Nokihara H, Nishioka Y Tags: Mol Clin Oncol Source Type: research

Comparison between stereotactic radiosurgery and whole-brain radiotherapy for 10-20 brain metastases from non-small cell lung cancer.
Abstract The efficacy and safety of stereotactic radiosurgery (SRS) in comparison with whole brain radiotherapy (WBRT) for brain metastases (BMs) remains unclear. The present study retrospectively reviewed 44 patients who received SRS or WBRT as an initial treatment for 10-20 BMs from non-small cell lung cancer between 2009 and 2016. Of the patients, 24 (54.5%) were treated with SRS and 20 (45.5%) were treated with WBRT. Overall survival (OS), time to intracranial progression (TTIP), neurological survival (NS), and prognostic factors were examined. OS did not significantly differ between the two groups: 7.3 months...
Source: Clinical Lung Cancer - April 12, 2019 Category: Cancer & Oncology Authors: Mizuno T, Takada K, Hasegawa T, Yoshida T, Murotani K, Kobayashi H, Sakurai T, Yamashita Y, Akazawa N, Kojima E Tags: Mol Clin Oncol Source Type: research

Interventional Pulmonology: A Focused Review for Primary Care Physicians.
This article provides a broad overview of the field to serve as a resource for primary care physicians. PMID: 30955509 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 9, 2019 Category: Cancer & Oncology Authors: Kniese CM, Musani AI Tags: Med Clin North Am Source Type: research

Lung Cancer.
Abstract Lung cancer is the world's leading cause of cancer death. Screening for lung cancer by low-dose computed tomography improves mortality. Various modalities exist for diagnosis and staging. Treatment is determined by subtype and stage of cancer; there are several personalized therapies that did not exist just a few years ago. Caring for the patient with lung cancer is a complex task. This review provides a broad outline of this disease, helping clinicians identify such patients and familiarizing them with lung cancer care options, so they are better equipped to guide their patients along this challenging jo...
Source: Clinical Lung Cancer - April 9, 2019 Category: Cancer & Oncology Authors: Nasim F, Sabath BF, Eapen GA Tags: Med Clin North Am Source Type: research

Occupational Lung Disease.
This article reviews the broad range of types of occupational lung diseases, including airways disease, pneumoconioses, and cancer. Common causes of occupational lung disease are reviewed with specific examples and clinical features. Emphasis on the importance of a detailed history to make an accurate diagnosis of an occupational lung disease is discussed. PMID: 30955520 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 9, 2019 Category: Cancer & Oncology Authors: Perlman DM, Maier LA Tags: Med Clin North Am Source Type: research

Hepatic Manifestations of Cystic Fibrosis.
Abstract Cystic fibrosis liver disease (CFLD) remains the third leading cause of death in patients with cystic fibrosis. Although most patients with CFLD present in childhood, recent studies suggest a second wave of liver disease in adulthood. There are no clear guidelines for diagnosing CFLD. Treatment options for CFLD remain limited, and while UDCA is widely used, its long-term benefit is unclear. Those who develop hepatic decompensation or uncontrolled variceal bleeding may benefit from liver transplant, either alone, or in combination with lung transplant. PMID: 30947876 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - April 6, 2019 Category: Cancer & Oncology Authors: Sakiani S, Kleiner DE, Heller T, Koh C Tags: Clin Liver Dis Source Type: research

Anemia is a poor prognostic factor for stage I non-small cell lung cancer (NSCLC) patients treated with Stereotactic Body Radiation Therapy (SBRT).
This study reports on the prognostic ability of haematological parameters for the largest known biopsy-proven stage-I medically inoperable cohort treated with SBRT.•After SBRT, the median values of Hb, ALC, ANC and TPC declined whereas the NLR and the PLR increased as compared to pre-SBRT.•Anemia along with other parameters was found to be a poor prognostic factor for local control despite treatment with SBRT to doses of>100 Gy BED10.•Simple and minimally invasive methods like a peripheral blood sample can provide prognostic information even for stage-I NSCLC patients.•Patient, tumor and treatment ...
Source: Clinical Lung Cancer - March 30, 2019 Category: Cancer & Oncology Authors: Pathak RS, Pantarotto JR, Cook G, Holmes O, Cross P, MacRae RM Tags: Clin Transl Radiat Oncol Source Type: research

Treatment of T3N0 non-small cell lung cancer with chest wall invasion using stereotactic body radiotherapy.
Conclusions: SBRT for CWI NSCLC is safe, with high early tumor control and low treatment-related toxicity. Most patients with pre-treatment chest wall pain experienced relief after SBRT, with no grade 3+ toxicity observed. PMID: 30859139 [PubMed] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - March 13, 2019 Category: Cancer & Oncology Authors: Kennedy WR, Gabani P, Nikitas J, Samson PP, Robinson CG, Bradley JD, Roach MC Tags: Clin Transl Radiat Oncol Source Type: research

Immunotherapy Toxicity.
Abstract The development of immunotherapy to target cancer has led to improved treatment of many types of malignancy. The immune checkpoint inhibitors are a class of medications that block cell signaling and allow the immune system to recognize and attack cancer cells. CTLA-4, PD-1, and PD-L1 inhibitors have been approved as treatment options in many different types of localized and advanced malignancies. Immune checkpoint inhibitors can be associated with unique side effects known as immune-related adverse events. Side effects most commonly occur in the skin, gastrointestinal tract, lung, and endocrine glands but...
Source: Clinical Lung Cancer - March 6, 2019 Category: Cancer & Oncology Authors: Mantia CM, Buchbinder EI Tags: Hematol Oncol Clin North Am Source Type: research

Novel Chimeric Gene Therapy Vectors Based on Adeno-Associated Virus and Four Different Mammalian Bocaviruses.
Abstract Parvoviruses are highly attractive templates for the engineering of safe, efficient, and specific gene therapy vectors, as best exemplified by adeno-associated virus (AAV). Another candidate that currently garners increasing attention is human bocavirus 1 (HBoV1). Notably, HBoV1 capsids can cross-package recombinant (r)AAV2 genomes, yielding rAAV2/HBoV1 chimeras that specifically transduce polarized human airway epithelia (pHAEs). Here, we largely expanded the repertoire of rAAV/BoV chimeras, by assembling packaging plasmids encoding the capsid genes of four additional primate bocaviruses, HBoV2...
Source: Clinical Lung Cancer - February 17, 2019 Category: Cancer & Oncology Authors: Fakhiri J, Schneider MA, Puschhof J, Stanifer M, Schildgen V, Holderbach S, Voss Y, El Andari J, Schildgen O, Boulant S, Meister M, Clevers H, Yan Z, Qiu J, Grimm D Tags: Mol Ther Methods Clin Dev Source Type: research

Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program.
CONCLUSION: Our experience suggests an encouraging efficacy of nintedanib/docetaxel in patients with adenocarcinoma NSCLC pretreated with platinum-based doublet chemotherapy and immunotherapy, reinforcing the importance of an optimal therapeutic sequence for managing advanced lung adenocarcinoma. PMID: 30771085 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 15, 2019 Category: Cancer & Oncology Authors: Corral J, Majem M, Rodríguez-Abreu D, Carcereny E, Cortes ÁA, Llorente M, López Picazo JM, García Y, Domine M, López Criado MP Tags: Clin Transl Oncol Source Type: research

Inference on covariate effect types for treatment effectiveness in a randomized trial with a binary outcome.
CONCLUSION: Our approach characterizes the covariate effect types in terms of the response types, and to what extent. In a randomized clinical trial with a binary outcome, our approach is a potentially valuable addition to standard subgroup or regression analysis. PMID: 30760066 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 13, 2019 Category: Cancer & Oncology Authors: Chiba Y Tags: Clin Trials Source Type: research

Patterns of follow-up care after curative radiotherapy  ± chemotherapy for stage I-III non-small cell lung cancer.
CONCLUSION: The follow-up of patients showed considerable variation between institutions. Routine imaging was not associated with subsequent curative treatment of events or improved overall survival. PMID: 30761737 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 13, 2019 Category: Cancer & Oncology Authors: Mohan S, Beydoun N, Nasser E, Nguyen A, Shafiq J, Vinod S Tags: Asia Pac J Clin Oncol Source Type: research

Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients?
Abstract PURPOSE: To evaluate the prognostic value of FDG PET/CT metabolic parameter compared to clinico-pathological risk factors in surgical margin-negative stage IA non-small cell lung cancer (NSCLC) patients. METHODS: 167 patients with consecutive FDG PET/CT scans from 2009 to 2015 performed for staging of NSCLC stage IA with plans for curative surgery were retrospectively reviewed. Maximum standardized uptake value (SUVmax) of primary tumor and mean SUV of liver were acquired from PET/CT. Tumor-to-liver SUV ratio (TLR) was calculated. Charts were reviewed to obtain basic patient characteristics (age, sex...
Source: Clinical Lung Cancer - February 13, 2019 Category: Cancer & Oncology Authors: Park HL, Yoo IR, Boo SH, Park SY, Park JK, Sung SW, Moon SW Tags: J Cancer Res Clin Oncol Source Type: research

Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers.
CONCLUSIONS: In summary, our study shows that loss of RBM3 expression predicts worse clinical outcome in LUAC patients. PMID: 30758670 [PubMed - as supplied by publisher] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 13, 2019 Category: Cancer & Oncology Authors: Melling N, Bachmann K, Hofmann B, El Gammal AT, Reeh M, Mann O, Moebius C, Blessmann M, Izbicki JR, Grupp K Tags: J Cancer Res Clin Oncol Source Type: research

MiR-223-3p functions as a tumor suppressor in lung squamous cell carcinoma by miR-223-3p-mutant p53 regulatory feedback loop.
CONCLUSIONS: Our study identified miR-223-3p, as a tumor suppressor gene, markedly inhibited cell proliferation and migration via miR-223-3p-mutant p53 feedback loop, which suggested miR-223-3p might be a new therapeutic target in LSCC bearing p53 mutations. PMID: 30755230 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 12, 2019 Category: Cancer & Oncology Authors: Luo P, Wang Q, Ye Y, Zhang J, Lu D, Cheng L, Zhou H, Xie M, Wang B Tags: J Exp Clin Cancer Res Source Type: research

Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
CONCLUSION: Anlotinib induced apoptosis and protective autophagy in human lung cancer cell lines. Autophagy inhibition further enhanced the cytotoxic effects of anlotinib, and potentiated the anti-angiogenic property of anlotinib through JAK2/STAT3/VEGFA signaling. PMID: 30755242 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 12, 2019 Category: Cancer & Oncology Authors: Liang L, Hui K, Hu C, Wen Y, Yang S, Zhu P, Wang L, Xia Y, Qiao Y, Sun W, Fei J, Chen T, Zhao F, Yang B, Jiang X Tags: J Exp Clin Cancer Res Source Type: research

SHMT1 inhibits the metastasis of HCC by repressing NOX1-mediated ROS production.
CONCLUSIONS: These data indicate that SHMT1 inhibits the metastasis of HCC by repressing NOX1 mediated ROS production. PMID: 30755243 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 12, 2019 Category: Cancer & Oncology Authors: Dou C, Xu Q, Liu J, Wang Y, Zhou Z, Yao W, Jiang K, Cheng J, Zhang C, Tu K Tags: J Exp Clin Cancer Res Source Type: research

DRAM2 acts as an oncogene in non-small cell lung cancer and suppresses the expression of p53.
CONCLUSIONS: DRAM2 plays an oncogenic role in NSCLC via regulating p53 expression. Therefore, DRAM2 may act as an oncogene in NSCLC and could serve as a prognostic factor and potential target for NSCLC treatment. PMID: 30755245 [PubMed - in process] (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - February 12, 2019 Category: Cancer & Oncology Authors: Wudu M, Ren H, Hui L, Jiang J, Zhang S, Xu Y, Wang Q, Su H, Jiang X, Dao R, Qiu X Tags: J Exp Clin Cancer Res Source Type: research

A candidate for lung cancer treatment: arsenic trioxide.
Abstract Arsenic trioxide (ATO), a highly effective drug in treating acute promyelocytic leukemia with low toxicity, demonstrates a significant effect on lung cancer. The anti-cancer mechanisms of ATO include inhibition of cancer stem-like cells, induction of apoptosis, anti-angiogenesis, sensitization of chemotherapy and radiotherapy, anti-cancer effects of hypoxia, and immunoregulation properties. In addition, some studies have reported that different lung cancers respond differently to ATO. It was concluded on numerous studies that the rational combination of administration and encapsulation of ATO have promisi...
Source: Clinical Lung Cancer - February 12, 2019 Category: Cancer & Oncology Authors: Huang W, Zeng YC Tags: Clin Transl Oncol Source Type: research

Encapsulated miR-200c and Nkx2.1 in a nuclear/mitochondria transcriptional regulatory network of non-metastatic and metastatic lung cancer cells.
CONCLUSIONS: Little is known about miR-200c involvement in regulatory processes. Nano miR-200c affects invasion and migration mechanisms. The expression of encapsulated miR-200c contributes to the inhibition/activation of Kras, EMT, Hippo, regulatory pathways and blockers of metastasis. Delivery of miR-200c increases the expression of miR-29b, an EMY regulator, and miR-1247, an inhibitor of cancer genes, both tumor suppressors involved in lung metastasis. Encapsulated miR-200c act on different proteins that regulates cell cycle pathways. These findings represent a part of a regulatory network providing new insights towards...
Source: Clinical Lung Cancer - February 11, 2019 Category: Cancer & Oncology Authors: D'Almeida O, Mothar O, Bondzie EA, Lieumo Y, Tagne L, Gupta S, Volkert T, Levine S, Tagne JB Tags: BMC Cancer Source Type: research

Sensors for Lung Cancer Diagnosis.
Abstract The positive outcome of lung cancer treatment is strongly related to the earliness of the diagnosis. Thus, there is a strong requirement for technologies that could provide an early detection of cancer. The concept of early diagnosis is immediately extended to large population screening, and then, it is strongly related to non-invasiveness and low cost. Sensor technology takes advantage of the microelectronics revolution, and then, it promises to develop devices sufficiently sensitive to detect lung cancer biomarkers. A number of biosensors for the detection of cancer-related proteins have been demonstrat...
Source: Clinical Lung Cancer - February 11, 2019 Category: Cancer & Oncology Authors: Capuano R, Catini A, Paolesse R, Di Natale C Tags: J Clin Med Source Type: research